Copyright
©The Author(s) 2022.
World J Gastroenterol. Sep 7, 2022; 28(33): 4787-4811
Published online Sep 7, 2022. doi: 10.3748/wjg.v28.i33.4787
Published online Sep 7, 2022. doi: 10.3748/wjg.v28.i33.4787
Figure 7 Diiminoquinone reduced tumor growth in non-obese diabetic severe combined immunodeficiency mice.
Non-obese diabetic severe combined immunodeficiency (NOD-SCID) mice (5 mice/group) were injected with 100 HCT116 generation 1 spheres. Tumor growth was monitored by measuring the tumor volume during 21 d of treatment (3 times per week) with either 20 mg/kg diiminoquinone (DIQ) or physiologic saline. Representative images of control and DIQ-treated mice at day 21. Data represent an average of two independent experiments and is reported as mean ± standard error of the mean (aP < 0.05, bP < 0.01, cP < 0.001).
- Citation: Monzer A, Wakimian K, Ballout F, Al Bitar S, Yehya A, Kanso M, Saheb N, Tawil A, Doughan S, Hussein M, Mukherji D, Faraj W, Gali-Muhtasib H, Abou-Kheir W. Novel therapeutic diiminoquinone exhibits anticancer effects on human colorectal cancer cells in two-dimensional and three-dimensional in vitro models. World J Gastroenterol 2022; 28(33): 4787-4811
- URL: https://www.wjgnet.com/1007-9327/full/v28/i33/4787.htm
- DOI: https://dx.doi.org/10.3748/wjg.v28.i33.4787